Trial Profile
Cytoreductive surgery and intraoperative hyperthermic peritoneal perfusion with doxorubicin HCL liposomes (DOXIL) for advanced gastrointestinal/gynecologic malignancies: Phase I study
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 19 Jan 2006
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary)
- Indications Gastrointestinal cancer; Gynaecological cancer
- Focus Adverse reactions
- 19 Jan 2006 New trial record.